Long-term abiraterone withdrawal syndrome

Abiraterone acetate (AA) is an androgen receptor axis inhibitor, indicated together with prednisone, for metastatic castration-resistant prostate cancer. Withdrawal syndrome for classical antiandrogen treatments is well known, but not so known for AA. Abiraterone withdrawal syndrome (AWS) could be related to simultaneous prednisone discontinuation or to an androgenic effect of AA metabolites.

A case is described of a patient with long-term AWS without prednisone discontinuation. The clinical and prostate-specific antigen (PSA) response allowed an 8-month delay in docetaxel treatment.

Prednisone did not play a role in AWS in this case. The long-term response allowed a delay in future treatment.

Journal of clinical pharmacy and therapeutics. 2018 May 02 [Epub ahead of print]

S Marin, R Querol, L Campins, M Miarons, A Font, P Lianes

Pharmacy, Consorci Sanitari del Maresme, Mataro, Catalunya, Spain., Oncology, Consorci Sanitari del Maresme, Mataro, Catalunya, Spain., Oncology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe